We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
ImmunityBio (IBRX) Moves 41.9% Higher: Will This Strength Last?
Read MoreHide Full Article
ImmunityBio (IBRX - Free Report) shares soared 41.9% in the last trading session to close at $8.54. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 7.1% loss over the past four weeks.
ImmunityBio’s sharp share price surge was driven by a major regulatory breakthrough after the European Commission granted conditional approval for its Anktiva plus BCG therapy to treat BCG-unresponsive non-muscle invasive bladder cancer. The decision expands the company’s commercial footprint to 33 countries and marks the first immunotherapy authorized in Europe for this indication, significantly strengthening its growth outlook. The approval was supported by strong clinical data showing high complete response rates and durable outcomes upon treatment with the therapy.
This immunotherapy company is expected to post quarterly loss of $0.08 per share in its upcoming report, which represents a year-over-year change of +46.7%. Revenues are expected to be $37.1 million, up 391.4% from the year-ago quarter.
Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.
For ImmunityBio, the consensus EPS estimate for the quarter has been revised 6.3% higher over the last 30 days to the current level. And a positive trend in earnings estimate revision usually translates into price appreciation. So, make sure to keep an eye on IBRX going forward to see if this recent jump can turn into more strength down the road.
ImmunityBio is part of the Zacks Medical - Biomedical and Genetics industry. Mirum Pharmaceuticals, Inc. (MIRM - Free Report) , another stock in the same industry, closed the last trading session 2.2% higher at $105.1. MIRM has returned 11.9% in the past month.
For Mirum Pharmaceuticals, the consensus EPS estimate for the upcoming report has changed +50.9% over the past month to $0.02. This represents a change of +104.1% from what the company reported a year ago. Mirum Pharmaceuticals currently has a Zacks Rank of #3 (Hold).
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
ImmunityBio (IBRX) Moves 41.9% Higher: Will This Strength Last?
ImmunityBio (IBRX - Free Report) shares soared 41.9% in the last trading session to close at $8.54. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 7.1% loss over the past four weeks.
ImmunityBio’s sharp share price surge was driven by a major regulatory breakthrough after the European Commission granted conditional approval for its Anktiva plus BCG therapy to treat BCG-unresponsive non-muscle invasive bladder cancer. The decision expands the company’s commercial footprint to 33 countries and marks the first immunotherapy authorized in Europe for this indication, significantly strengthening its growth outlook. The approval was supported by strong clinical data showing high complete response rates and durable outcomes upon treatment with the therapy.
This immunotherapy company is expected to post quarterly loss of $0.08 per share in its upcoming report, which represents a year-over-year change of +46.7%. Revenues are expected to be $37.1 million, up 391.4% from the year-ago quarter.
Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.
For ImmunityBio, the consensus EPS estimate for the quarter has been revised 6.3% higher over the last 30 days to the current level. And a positive trend in earnings estimate revision usually translates into price appreciation. So, make sure to keep an eye on IBRX going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
ImmunityBio is part of the Zacks Medical - Biomedical and Genetics industry. Mirum Pharmaceuticals, Inc. (MIRM - Free Report) , another stock in the same industry, closed the last trading session 2.2% higher at $105.1. MIRM has returned 11.9% in the past month.
For Mirum Pharmaceuticals, the consensus EPS estimate for the upcoming report has changed +50.9% over the past month to $0.02. This represents a change of +104.1% from what the company reported a year ago. Mirum Pharmaceuticals currently has a Zacks Rank of #3 (Hold).